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are not good candidates for LVAD therapy owing 
to their relatively small LV cavity sizes.1
Neprilysin (NEP) is a membrane ‑bound, zinc‑
‑dependent endopeptidase that cleaves peptides 
with a molecular weight below 3000 Da.7 NEP 
is not only a ubiquitous enzyme, as it has been 
found in the brain, heart, lungs, peripheral cir‑
culation, adrenal glands, thyroid gland, gastroin‑
testinal tract, and arthritic synovium, but it also 
has an important enzymatic role in numerous bi‑
ological reactions.7 So far, NEP is best known for 
its activity in the cardiovascular system where it 
degrades natriuretic peptides (NPs), angioten‑
sins, bradykinin, endothelin, and adrenomedul‑
lin.8 However, NEP is also involved in the nervous 
system, where it acts on endorphins, enkephalins, 
oxytocin, and neurokinin; in the gastrointestinal 
system, where it degrades gastrin ‑releasing pep‑
tide, gastric inhibitory peptides, and cholecysto‑
kinin; in the respiratory system, where it acts on 
substance P and other tachykinins; or in cleaving 
metabolic peptides, such as glucagon, glucagon‑
‑like peptide, β ‑lipotropin, and somatostatin.7,9 
In healthy individuals, but more importantly in 
those with HF, atrial, B ‑type, and C ‑type NPs (ANP, 
BNP, and CNP, respectively) act via NP receptors 
to exert largely beneficial effects, such as natri‑
uresis, diuresis, vasodilatation, and suppression 
of the RAAS and sympathetic nervous system.10 
NEP is responsible for the proteolytic cleavage of 
NPs, and its bioactivity is considerably enhanced 
in HF.9 Of note, avidity of NEP for a particular NP 
is not identical: it is the highest for CNP and ANP, 
while BNP is relatively resistant to NEP.9 Thus, in‑
hibition of NEP (NEPi) should increase the level 
of NPs and bradykinins (although the beneficial 
role of bradykinin in HF is less well documented), 
which are endogenous, protective agents counter‑
ing the negative effects of persistent neurohor‑
monal overactivation in HF.
The value of the NEPi has been tested for over 
20 years. However, the initial results were not 
satisfactory because sole NEPi (monotherapy) 
lacked clinical efficacy.11 Therefore, newer agents 
To the Editor Hypertrophic cardiomyopathy 
(HCM) is an often benign and oligosymptomatic 
or even asymptomatic condition with normal life 
expectancy.1,2 On the other hand, some patients 
are characterized by adverse clinical profiles and 
life ‑threating complications. Those profiles can 
be broadly divided into left ventricular (LV) out‑
flow tract obstruction, myocardial ischemia and 
angina, atrial fibrillation and stroke, ventricular 
arrhythmias and sudden cardiac death, and last 
but not least heart failure (HF).1
In a minority of patients with HCM, the ini‑
tially small hypertrophied and hypercontractile 
LV over time comes to display a dilated, thin‑
‑walled, and hypocontractile phenotype.1 This 
phase, called end ‑stage, burnout, or hypokinetic‑
‑dilated, is characterized by progressive and usu‑
ally severe HF symptoms.1,2 Despite the absence 
of randomized controlled trials, drug manage‑
ment typically includes β ‑blockers and multilevel 
inhibition of the renin–angiotensin–aldosterone 
system (RAAS) including angiotensin ‑converting 
enzyme inhibitors (ACEIs), angiotensin receptor 
blockers (ARBs), and mineralocorticoid receptor 
antagonists (MRAs), alongside loop diuretics and 
digoxin.1,3 In patients with symptomatic HF and 
broad QRS complex, cardiac resynchronization 
therapy (CRT) was found to be beneficial, both 
for improvement of symptoms and prognosis.4 
Small studies have shown the moderate benefits 
of CRT in a subset of patients with typical left 
bundle branch block and LV ejection fraction (EF) 
of less than 50%.5 Orthotopic heart transplanta‑
tion (HTx) is an established mode of treatment in 
severe cases of end ‑stage HCM; however, due to 
a shortage of eligible organs, this mode of treat‑
ment is restricted. Moreover, graft rejection due 
to acute cellular reaction, susceptibility to infec‑
tion caused by prolonged immunosuppression, 
vasculopathy, and neoplasms substantially lim‑
it long ‑term effects of HTx.6 The advent of me‑
chanical LV assist devices (LVADs) is improving 
the poor prognosis of the majority of patients 
with severe HF. Still, patients with end ‑stage HCM 
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years were uneventful. Two years before presen‑
tation, she began to notice breathlessness on ex‑
ertion. An echocardiogram showed a mildly en‑
larged LV cavity and an EF of 40%. Thus, the tran‑
sition to end ‑stage phase was diagnosed. Thera‑
py with a β ‑blocker, ACEI, and MRA was initiated. 
Due to a narrow QRS complex, she was not re‑
ferred for CRT. Despite treatment, her function‑
al performance declined steadily. Eight months 
later, she was hospitalized due to severe dyspnea. 
On presentation, she showed left‑ and right ‑sided 
congestive HF (New York Heart Association func‑
tional class IV). Her N ‑terminal pro ‑B‑type natri‑
uretic peptide (NT ‑proBNP) level was 845 pg/ml 
[<125]. On echocardiogram, the LV cavity was 
enlarged (end ‑diastolic diameter, 62 mm) and 
EF was 30%. At first she was decongested with 
a moderate dose of loop diuretics. After a few 
days, a 6 ‑minute walk test was performed, which 
revealed significant impairment of exercise toler‑
ance (distance, 320 meters; Borg scale, 7). Based 
on emerging symptoms, gradual LV deterioration 
despite conventional treatment, and poor prog‑
nosis, the patient was scheduled for elective HTx. 
LVAD therapy was excluded by the surgeons due 
to a relatively small LV cavity, which could inter‑
fere with the device. 
Despite a  lack of previous reports, we de‑
cided on an extraordinary approach, and after 
the patient’s consent, we put her on a trial treat‑
ment with ARNI. After a 24 ‑hour washout peri‑
od from ACEI, we initiated the smallest dose of 
ARNI (Entresto, Novartis, 24/26 mg, twice dai‑
ly). She tolerated the drug well with no signs of 
hypotension. One month later, she reported feel‑
ing minimally better. Three months later, she re‑
ported a marked improvement in symptoms and 
exercise tolerance. A 6 ‑minute walk test revealed 
an increase of distance to 410 meters with a Borg 
scale of 3. On echocardiogram, a reduction of end‑
‑diastolic diameter to 58 mm and EF to 35% was 
observed. Moreover, the NT ‑proBNP level de‑
creased to 248 pg/ml. The patient did not com‑
plain of orthostatic hypotension or any other 
drug ‑related untoward effects. Therefore, the de‑
cision was made to up titrate the dose of ARNI 
to 49/51 mg, twice daily. Due to substantial im‑
provement, the HTx has been temporarily sus‑
pended, while the patient remained under close 
monitoring.
As far as we are aware, ARNI has not been used 
in patients with end ‑stage HCM before. Clearly, 
the results of this 3 ‑month ARNI treatment pre‑
sented here need to be interpreted with caution; 
still, we showed that ARNI was safe and moder‑
ately efficacious, at least in this case. Therefore, 
our preliminary results may show promise for 
patients with end ‑stage HCM. We believe that 
there is clearly a case to be made for further ran‑
domized studies in this patient group. Howev‑
er, such studies will be relatively difficult to un‑
dertake due to a low number of eligible patients, 
even at referral centers.
that combine NEPi and anti ‑RAAS activity via ei‑
ther anti ‑ACEI or ARB activity, called vasopepti‑
dase inhibitors, have been developed and tested 
in HF.9 In the medium ‑sized IMPRESS study,12 
omapatrilat (vasopeptidase inhibitor) significant‑
ly reduced the rates of composite endpoint (death 
and HF hospitalization) compared with lisino‑
pril (ACEI) alone. However, in the much larger 
OVERTURE study,13 omapatrilat was not superi‑
or to enalapril (ACEI) alone in reducing the risk 
of primary clinical event. Furthermore, any clin‑
ical benefit of omapatrilat was overshadowed by 
the significant increase of adverse effects, includ‑
ing severe angioedema and hypotension.13 There‑
fore, the combination of NEPi and ACEI was aban‑
doned due to lack of safety.
In the recent years, a novel class of agents act‑
ing on the RAAS and NEPi, namely, angioten‑
sin receptor neprilysin inhibitors (ARNIs), has 
shown robust evidence for safety and clinical ef‑
ficacy. PARADIGM ‑HF14 has been so far the larg‑
est study (n = 8442) on HF that tested the novel 
combination of sacubitril (NEPi) and valsartan 
(ARB) versus enalapril (ACEI) in symptomatic pa‑
tients with HF and reduced EF due to ischemic or 
dilated cardiomyopathy. Importantly, the study 
was prematurely terminated due to overwhelm‑
ing benefit of ARNI. ARNI was clearly superior to 
enalapril in improving prognosis (hazard ratio for 
all ‑cause mortality, 0.84; 95% confidence inter‑
val, 0.76–0.93; P <0.001), reducing the number 
of hospitalizations for HF and improving symp‑
toms and physical capacity.14
Despite millions invested in the new chemi‑
cal compounds and numerous clinical trials in 
the field of HF, ARNI is one of the very few drugs 
that have recently been actually confirmed to be 
safe and effective. Thus, the European Society of 
Cardiology as well as the American College of Car‑
diology and American Heart Association prompt‑
ly recognized the new drug in the HF armamen‑
tarium and independently developed new recom‑
mendations for incorporation of ARNI into HF 
management. Although minimal differences can 
be noted within original texts of the guidelines, 
both Americans and Europeans recommend ARNI 
(class I B) as a replacement for an ACEI (or ARB) 
for ambulatory patients with HF and those with 
reduced EF who remain symptomatic despite opti‑
mal treatment.3,15 To date, the application of ARNI 
has not yet been reported in end ‑stage HCM. Thus, 
we would like to share a first ‑in ‑human experi‑
ence of ARNI treatment in a middle ‑aged wom‑
an with end ‑stage HCM and overt HF.
The case described here is that of a 43 ‑year old 
woman diagnosed with nonobstructive HCM 12 
years earlier, following a first ‑ever out ‑of ‑hospital 
sudden cardiac arrest and successful reanimation. 
Upon discharge, she had been implanted with 
a cardioverter ‑defibrillator. An initial echocardio‑
gram had revealed a small LV cavity, moderately 
hypertrophied basal and mid ‑segments of the sep‑
tum, and normal systolic function. The next 10 
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